.png){kind=icon}
.png){kind=icon}
Return
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial
.png){kind=icon}
PRE
AI
DOI：10.1080/14796694.2025.2592527.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
AimsThis retrospective, chart-review study evaluated real-world outcomes post-frontline brigatinib in ALTA-1L.MethodsPatients from ALTA-1L were followed after brigatinib discontinuation. Outcomes evaluated for second-line (2L) treatment included real-world overall response rate (rwORR), time to treatment discontinuation (rwTTD), and progression-free survival (rwPFS).ResultsForty of 48 patients received subsequent systemic anticancer therapies; 30 received 2L ALK tyrosine kinase inhibitors (TKIs), mostly lorlatinib (n = 16) or alectinib (n = 8), and 11 received 2L non-ALK TKI therapy (one with alectinib). rwORR was 33% with 2L ALK TKIs and 0% with 2L non-ALK TKI therapy. Median (95% confidence interval [CI]) 2L rwTTD was 34.7 months (4.6-not reached [NR]) for ALK TKIs (lorlatinib, 37.2 months [6.0-NR]; alectinib, NR [1.1-NR]; crizotinib, 2.8 months [2.0-NR]) and 4.4 months (1.4-6.0) for 2L non-ALK TKI therapy. Median (95% CI) 2L rwPFS was 16.1 months (4.4-NR) with ALK TKIs (lorlatinib, 25.6 months [3.8-NR]; alectinib, 16.1 months [1.1-NR]; crizotinib, 2.4 months [2.0-NR]) and 6.1 months (1.7-NR) with 2L non-ALK TKI therapy.ConclusionsFollowing brigatinib discontinuation, most patients initiated a second ALK TKI. Patients treated with 2L second- or third-generation ALK TKIs post-brigatinib experienced prolonged clinical benefit.Clinical trial registrationclinicaltrials.gov identifier: NCT02737501.
Keywords:
Lorlatinib
alectinib
crizotinib
non-small cell lung carcinoma
treatment sequencing
Journal
IF:
2.6
Papers:
5.2K
Citations:
7.8K
Organization
View more organizations